RxDoctor Payments Data

Cherry Yu, MD

Neurology · Nashville, TNNPI 1164956678

Payments from drug & device makers

$19,627in general payments, 2019–2025

Across 52 payments — averaging $377.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$17K
  • Medtronic$1K
  • UCB, Inc.$804
  • Abbott$332
  • Neurocrine Biosciences, Inc.$319
  • Teva Pharmaceuticals USA, Inc.$248
  • plus $101 from 2 others

What the payments were for

  • Grants$15,00076%
  • Travel & lodging$2,44512%
  • Food & beverage$2,18211%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,627 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$61,520
Medicare patients
249
Services billed
750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine23$149,059
Austedo XrDeutetrabenazine13$105,532
RytaryCarbidopa/Levodopa57$79,835
NuplazidPimavanserin Tartrate15$70,113
Carbidopa19$10,963
Carbidopa-LevodopaCarbidopa/Levodopa232$10,294
Carbidopa-Levodopa ErCarbidopa/Levodopa75$3,675
Ropinirole ErRopinirole Hcl11$2,279
AmantadineAmantadine Hcl37$1,859
Propranolol Hcl ErPropranolol Hcl24$1,451
RivastigmineRivastigmine Tartrate17$937
Primidone38$668
Gabapentin39$624
Propranolol Hcl24$366
Donepezil Hcl19$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$248$254,59136 claims
Acadia Pharmaceuticals IncNuplazid$18$70,11315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →